|
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
Jan 2020 |
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
|
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2021 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Apr 2023 |
The Oncologist |
Myelodysplastic Syndromes (MDS) |
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Apr 2023 |
The Oncologist |
Myelodysplastic Syndromes (MDS) |
|
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study |
Oct 2020 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
Jan 2021 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
